Exclusive


Medical Cannabis Tech and Data Company Going Public Soon

April 28th, 2021 - Robin Lefferts

If cannabis is to be accepted by the medical community (meaning patients, doctors, researchers, pharma companies, regulators…), there is much to be done in terms of testing the plant, standardizing dosages, and cataloging its effects. After decades of prohibition, scientists are racing to determine and document the potential benefits of cannabis in the treatment of […]

Decibel’s Record Financial Results Reflect Strength of Craft Cannabis Market

April 26th, 2021 - Robin Lefferts

  A few years ago, as companies prepared for legalization of adult-use cannabis in Canada, there was a lot of talk about the eventual commodification of flower due to overproduction. The thinking was that price would be the driving factor in determining market success, but it hasn’t really played out that way to this point. […]

Microdosing: The Next Revolution in Psychedelics

April 22nd, 2021 - Ryan Allway

The psychedelics industry has experienced a renaissance over the past few years as researchers have opened a pandora’s box of potential. From major depression to generalized anxiety to post-traumatic stress disorder, emerging research suggests that psychedelic substances could have a significant beneficial impact on hard-to-treat mental health disorders. As states liberalize their psychedelics regulations, microdosing […]

Opportunity Abounds in Cannabinoid Topicals Market

April 21st, 2021 - Ryan Allway

Cannabis topicals, including both CBD and THC containing products, are one of the fastest growing segments of the industry. According to Million Insights, the CBD skincare market is projected to grow at a 32.9% CAGR between 2019 and 2025 to reach $1.7 billion. The steep growth in the sector has led to some level of […]

Cookies and Gage Growth Corp.: A Recipe for Success in Michigan

April 19th, 2021 - Robin Lefferts

  National branding is very difficult to achieve in the cannabis industry. The federal ban on interstate cannabis commerce is the major obstacle, as most companies are unwilling or unable to set up full operations in multiple states. If a company were to choose the multi-state operator approach in the current environment, the varying regulations […]

KI findet die Nadel im Heuhaufen

April 15th, 2021 - Makenzie Branch

   Jedes Jahr werden Tausende von Molekülen als Medikamentenkandidaten für eine Vielzahl von Krankheiten hergestellt, synthetisiert und getestet. MagicMed Industries bringt diesen pharmazeutischen Entwicklungsansatz auf dem Gebiet der Psychedelika zum Einsatz, um neue therapeutische Alternativen für Patienten mit Problemen der Gehirn- und psychischen Gesundheit zu schaffen. Die Entdeckung der richtigen Moleküle ist jedoch ein gewaltiges […]

AI to Find Needle in Haystack

April 15th, 2021 - Makenzie Branch

Every year, thousands of molecules are being created, synthesized and tested as drug candidates for a vast number of ailments. MagicMed Industries brings this pharmaceutical development approach to the field of psychedelics to create new therapeutic alternatives for patients with brain and mental health indications. However, discovering the right molecules is a massive undertaking. It […]

Psychedelics Then & Now: From Ancient Times to the Psychedelic Renaissance

April 14th, 2021 - Ryan Allway

Psychedelics have become one of the most promising classes of drugs in a generation, as well as an exciting new industry for investors. Despite their resurgence among researchers and investors, psychedelics have been used for thousands of years before they were criminalized in the 1970s in the United States and around the world. Let’s take […]

Fiore Cannabis: A Small Customer-focused Team Executes an Impressive Turnaround

April 12th, 2021 - Ryan Allway

The cannabis industry followed a familiar and predictable path over the past few years. In the early years, companies raised significant amounts of capital to build massive indoor cultivation operations in an attempt to scale at all costs. A handful of companies succeeded but most shut down due to a lack of capital, poor product […]

Psychedelics Wellness Company Delic: Proven Management Team with a Star-Studded Board

April 9th, 2021 - Ryan Allway

The psychedelics  sector is quickly evolving into a multi-billion-dollar industry with a growing number of publicly traded companies. As with any new industry, there are many companies backed by little more than financiers looking to make a quick dollar before moving on to the next opportunity, which makes it important for investors to know who’s […]

The Rise of Specialization in Cannabis (and How to Invest)

April 5th, 2021 - Ryan Allway

Many early cannabis companies were forced into vertical-integration due to regulatory constraints. While it may make sense for cultivators to create extracts, it doesn’t always make sense for them to own commercial kitchens for confections or bottling machines for beverages, given the high capital costs and low return on investment. Most cultivators can earn a […]

Ovation Science Takes Topical Cannabis to the Next Level with Its Patented Drug Delivery Technology

March 23rd, 2021 - Ryan Allway

Cannabinoids have become some of the most popular health and wellness products in the world. For example, CBD-infused topicals are expected to reach $4.5 billion in sales by 2025, according to Cultivating Wellness, which represents a 540% increase since 2020. At the same time, topicals infused with THC or combinations of CBD and THC are […]

The Psybrary™: 12 Choose Your Own Adventure Stories, Millions of Endings

March 11th, 2021 - Liam Harrison

MagicMed’s PsybraryTM is a remarkable and impressive achievement that, pending patent approval, could provide patent protection to more than an estimated 125 million derivatives. While 125 million derivatives is a big number, two clarifications should be made. Firstly, this number does not indicate that they have locked a small army of scientists away to fulfill […]

Delic’s Vision Comes Into Focus With a Flurry of Acquisitions

March 11th, 2021 - Ryan Allway

  Investors have many different options when it comes to building exposure into the psychedelics sector within their portfolios. While some companies are undergoing large-scale and years-long clinical trials to prove efficacy, others are opening wellness clinics or cultivating mushrooms in legal jurisdictions. Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) is a relatively new player […]

Why DELIC’s Latest Acquisition is a Complete Game-Changer

March 8th, 2021 - Ryan Allway

The Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) team has been at the forefront of the cannabis industry for over a decade. After building High Times into the giant it is today, they founded DELIC as an umbrella platform to target the nascent psychedelics industry through a combination of media properties, high-profile events, wellness clinics […]

Do International Cannabis Companies Deserve More Attention?

March 2nd, 2021 - Ryan Allway

Since the legal cannabis industry burst onto investors’ radar in 2014 the U.S. market and the Canadian markets have been the primary focus. The potential of the U.S. market in terms of sheer size, and the Canadian national recreational program and export opportunities have captured investor attention.  Interestingly, there are some U.S. and Canadian companies […]

Es gibt keine magische Antwort auf die Frage “Kann ich Zauberpilze patentieren lassen?”

February 26th, 2021 - Ryan Allway

“Patent angemeldet” ist ein Ausdruck, mit dem Sie wahrscheinlich vertraut sind. Sie haben gesehen, wie es auf der Seite eines Dinges im Einkaufszentrum gestempelt wurde, oder Sie haben es in der Fernsehsendung gehört, die Sie gerade anschauen, und Sie denken sich: „Wow, ich wünschte, ich könnte etwas erfinden, das jeder für wirklich cool hält.“ Die […]

There’s no Magic Answer to the Question, “Can I Patent Magic Mushrooms?”

February 24th, 2021 - Ryan Allway

“Patent pending” is a phrase you are likely familiar with. You have seen it stamped on the side of some doodad at the mall or heard it on the TV show that you are binge watching, and you think to yourself, “Wow, I wish I could invent something that everyone thinks is really cool”. Most […]

How California is Dominating the Cannabis Brand Landscape

February 24th, 2021 - Ryan Allway

California is well known for its brand dominance—from its Hollywood studios to its Napa Valley wines. As a tastemaker across industries, the state’s cannabis brands are well-positioned to follow in these footsteps and expand across the United States if and when the federal government legalizes cannabis nationwide. At the same time, manufactured products including gummies, […]

Building the ‘Omnichannel’ of Legal Cannabis in California

February 23rd, 2021 - Ryan Allway

  The cannabis industry is projected to be worth more than $73 billion by 2027, according to Grand View Research, which represents an 18.1% compound annual growth rate. Within this growing market, California generates nearly a third of all cannabis sales in the United States—or roughly the combined sales of Colorado, Washington, and Oregon. While […]

Cannabis 3.0: Investing in Profitability

February 23rd, 2021 - Ryan Allway

If you’ve been following the public cannabis markets for the past decade, you’ve seen a myriad of changes that can be bundled into a few major categories: The Canadian build up, the rise of the US MSO and the race to get profitable.  During the Canadian build up, call it Cannabis 1.0, it was all […]

Look for Bottom Line Performance in Cannabis Companies

February 22nd, 2021 - Robin Lefferts

  Some key features of Decibel Cannabis Company: Defining the upper echelon of premium cannabis brands with its own brand, Qwest Among the few profitable cannabis companies with growth ahead Short supplied with leading flower pricing – adding 4x flower production #1 and #3 in vapes and concentrates with 30+ product SKUs to come The […]

Revive Therapeutics Aims to Bring Psychedelics to Market

February 17th, 2021 - Ryan Allway

The psychedelic drug market is projected to grow at a 16.3% compound annual growth rate to reach nearly $7 billion by 2027, according to Data Bridge Market Research. While there are a growing number of publicly traded companies in the space, the best opportunities have the right combination of experience, intellectual property and clinical trials. […]

Kaya Reaches Beyond Oregon

February 17th, 2021 - Ryan Allway

  In early 2014, in a small office in Hollywood, Florida, the management of what is today Kaya Holdings made the strategic decision to transition their existing small-cap publicly traded biofuels company away from alternative energy and exclusively toward the cultivation and retail of legal cannabis. This was no ordinary decision; Colorado and Washington had […]

Psychedelics: Significant Investor Interest Despite the Pandemic

February 16th, 2021 - Ryan Allway

  The COVID-19 pandemic may be ravaging large swaths of the economy, but the stock market has consistently hit new record highs. After spending several years under-the-radar, the psychedelics industry is experiencing a renaissance driven by a combination of FDA-driven catalysts and soaring investor interest in a new class of potential blockbuster therapeutics.  Let’s take […]

ManifestSeven Doubles Down on Emerald Triangle with New Facility

February 9th, 2021 - Ryan Allway

California’s legal cannabis industry is on track to reach $7.2 billion in sales by 2024, according to Arcview Market Research and BDS Analytics, which represents a 19% compound annual growth rate. The Emerald Triangle region is widely considered to be the epicenter of that growth with its ideal microclimate and world-class operators. Let’s take a […]

Royalty Streaming: A Different Way to Get Exposure to the Cannabis Market

February 9th, 2021 - Ash Stringer

  When cannabis legalization started to gain momentum in 2012 with Washington and Colorado legalizing recreational marijuana, everyone knew it was going to be a big industry. For nearly a decade now, the investment community has ridden the volatility of the emerging market that generated $13.8 billion in sales in North America in 2019. Analysts […]

Combining Traditional Therapies with Psychedelics: SiloPharma Targeting CNS and Neurological Disorders

February 4th, 2021 - Ryan Allway

“Psychedelics” is a buzz word on Wall Street, but much like legal cannabis or bitcoin and blockchain a decade ago, it remains greatly misunderstood as the market emerges. There was a time when psychedelics were only perceived as part of the illicit drug culture. That stigma is disappearing. Loaded with promise, the burgeoning market includes […]

Next Green Wave: A Hidden Gem in the Cannabis Industry

January 28th, 2021 - Ryan Allway

  The cannabis industry is projected to hit $30 billion in sales by 2023, according to Marijuana Business Daily, with California representing about 34% of U.S. sales. While there are many publicly traded companies in the space, there are only a handful that are growing and profitable with a truly experienced team both in the […]

3 Areas Psychedelics Could Address (and How to Invest in Them)

January 27th, 2021 - Ryan Allway

  Psychedelics have shown promise in the treatment of many treatment-resistant conditions, ranging from major depressive disorder to fibromyalgia. The therapeutic markets for these conditions could be worth billions of dollars per year, which has drawn the interest of both researchers and investors across North America. Let’s take a look at three areas where psychedelics […]


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading